Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

Trigo, J.Cho, B. C.Park, K.Girard, N.Viteri, S.Garrido, P.Krebs, M. G.Thayu, M.Knoblauch, R. E.Xie, J.Bauml, J. M.Schnepp, R. W.Londhe, A.Mahadevia, P.Leighl, N.2023-05-032023-05-032022-04-020923-7534http://hdl.handle.net/10668/21888enRisk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)conference outputopen access10.1016/j.annonc.2022.02.0291569-8041http://www.annalsofoncology.org/article/S0923753422001454/pdf778453100021